Advertisement

PharmacoEconomics & Outcomes News

, Volume 800, Issue 1, pp 22–22 | Cite as

Indacaterol/glycopyrronium: better outcomes, lower cost in COPD

Clinical study
  • 27 Downloads

Reference

  1. Tee A, et al. Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore. Singapore Medical Journal : 16 Mar 2018. Available from: URL: http://doi.org/10.11622/smedj.2018022

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations